HERVolution Therapeutics, a biotechnology company pioneering human endogenous retrovirus (HERV)-targeting immunotherapies for oncology, metabolic diseases, and longevity, today announced the ...
Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...
Immunic Inc. IMUX on Tuesday announced it appointed Michael Panzara as its Chief Medical Officer, effective April 24, 2026, as the company looks to advance its clinical and regulatory strategy. The ...
MELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today ...
In today’s ACT Brief, we highlight where AI is delivering real gains in protocol development, how geopolitical disruption is ...
Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight The follicular lymphoma clinical trial analysis report delivers important insights into ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results